A Health Affairs study published Nov. 3 examined an increase in states banning prior authorizations in private insurance plans for opioid use disorder medications.
The aggravating prior authorization process includes one step that merits scrutiny and potentially regulatory action: the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback